Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation — A to Z Product Catalog

Marketed Products

• SYMJEPI® 0.3 mg (epinephrine injection)
  • Indication: Emergency treatment of anaphylaxis (patients weighing ≥66 lb / ≥30 kg)
  • Dose/Form: 0.3 mg intramuscular single-use syringe

• SYMJEPI® 0.15 mg (epinephrine injection)
  • Indication: Emergency treatment of anaphylaxis (patients weighing 33–65 lb / ~15–30 kg)
  • Dose/Form: 0.15 mg intramuscular single-use syringe

• ZIMHI® (naloxone HCl injection)
  • Generic: Naloxone hydrochloride, high-dose
  • Indication: Opioid overdose reversal
  • Dose/Form: 5 mg in 0.5 mL intramuscular injection, single-use compact device

Investigational Programs (Prior to or during DMK Merger)

• Tempol (APC-400)
  • Generic/Type: Tempol (a redox-cycling nitroxide with antioxidant/antiviral activity)
  • Indication (studied): COVID-19 treatment (Phase 2/3)
  • Dose/Form: Oral capsule; trial dosing as per Phase 2/3 protocol (development halted early due to lack of efficacy)

Post-Merger Pipeline (via DMK integration)

• DPI-125
  • Type: Small molecule neuropeptide analogue
  • Indication: Opioid Use Disorder (OUD); potential for moderate to severe pain
  • Dose/Form: Clinical stage; dosing not yet disclosed

• DPI-221
  • Type: Small molecule neuropeptide analogue
  • Indication: Bladder control disorders
  • Dose/Form: Preclinical / early development; dose unspecified

• DPI-289
  • Type: Small molecule neuropeptide analogue
  • Indication: End-stage Parkinson’s disease
  • Dose/Form: Preclinical / early development; dose unspecified

•